Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
11Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Kyntra Bio, Inc. (KYNB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
3Distinct source URLs
7High confidence
0.747Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Kyntra Bio, Inc. Suppliers
Ticker
Name
Confidence
Evidence
NOVAQUEST
NOVAQUEST
92%
Company entered into a Revenue Interest Financing Agreement (the “RIFA”) with an affiliate of NovaQuest Capital Management ("NovaQuest"), pursuant to which the Company granted NovaQuest 22.5 % of its…
straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, our revenue for continuing operations was substantially related to our collaboratio…
Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, ou…
Reciprocal relationship from MS-PK graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from MS-PK graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from MS-P…
Kyntra Bio, Inc. Customers
Ticker
Name
Confidence
Evidence
FALIKANG
FALIKANG
90%
Our proportionate share of the reported profits or losses of Falikang, was included in the discontinued operations in the condensed consolidated statement of operations. See Note 2, Discontinued Oper…
In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China ("AstraZeneca Ch…
Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from AZN grap…
Reciprocal relationship from MS-PK graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from MS-PK graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from MS-P…
ASTELLAS-PHARMA-INC
ASTELLAS-PHARMA-INC
62%
advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …
ASTRAZENECA-TREASURY-LIMITED
ASTRAZENECA-TREASURY-LIMITED
62%
advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …
Reciprocal relationship from ASTS graph: Reciprocal relationship from KYNB graph: advantages of the product candidate over alternative treatments, including any similar generic treatments; • the incl…
Reciprocal relationship from BAC graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from BAC graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from BAC grap…
BOFA-SECURITIES-INC
BOFA-SECURITIES-INC
62%
n, or 1,529%, for the three months ended March 31, 2026, compared to the same period a year ago, primarily due to the cost associated with the intermediates drug product revenue of $3.3 million and t…
FIBROGEN-CHINA-ANEMIA-HOLDINGS-LTD
FIBROGEN-CHINA-ANEMIA-HOLDINGS-LTD
62%
n, or 1,529%, for the three months ended March 31, 2026, compared to the same period a year ago, primarily due to the cost associated with the intermediates drug product revenue of $3.3 million and t…
FORTIS-THERAPEUTICS-INC
FORTIS-THERAPEUTICS-INC
62%
advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …
Kyntra Bio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
KYNB-DEBT
Debt stack $75.0M
90%
Market cache reports total debt of $75.0M.
KYNB-DEBT-10597
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2015-12-31.
Kyntra Bio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kyntra Bio, Inc..
Kyntra Bio, Inc. Ownership
Holder
Name
Confidence
Evidence
KYNB-OWNER-ARMISTICE-CAPITAL-LLC
ARMISTICE CAPITAL, LLC
90%
13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 34 tracked holders.
